ClinicalTrials.gg
RecruitingNCT05896397EADCUpdated Jun 4, 2026

European Aortic Data Collection Project

An observational study in Complex Abdominal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm and Aortic Arch Aneurysm, sponsored by Cook Research Incorporated. Recruiting at 18 sites in 6 countries. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Cook Research Incorporated (part of Cook Group Incorporated) · Observational

From the registry’s dates

  • Started May 2023; still recruiting 3 years 5 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and performance of Cook's various Custom-Made Stent-graft Devices (CMD) used for endovascular treatment of the aorta and related diseases by collecting information on the real-world use of the devices.

The study results will be used to support the continuation of the CMDs on the market. In addition, the study will support the manufacturers obligation for post market product surveillance as well as Cook's technology development.

02

Conditions studied

  • Complex Abdominal Aortic Aneurysm
  • Thoracoabdominal Aortic Aneurysm
  • Aortic Arch Aneurysm
  • Chronic Aortic Dissection

Keywords

  • Complex aortic repair
  • Aortic aneurysm
  • Aortic dissection
  • Fenestrated/branched endograft
  • Custom-made endovascular graft
03

In context

Aortic Aneurysm, Thoracoabdominal

63 studies on the registry are indexed under Aortic Aneurysm, Thoracoabdominal; 31 are open to participants now.

This study's planned enrollment of 600 is above the median of 100 across 20 observational studies indexed under Aortic Aneurysm, Thoracoabdominal.

Browse Aortic Aneurysm, Thoracoabdominal studies →

Lead sponsor

Cook Research Incorporated is the lead sponsor of 33 studies on the registry; 4 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients receiving a Cook custom made endovascular graft within the scope of the study in a maximum of 20 clinical sites in Europe.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1. Patients who will be treated with a Cook CMD

Exclusion criteria

Exclusion Criteria:

  1. Patients who declare they are unable to complete clinical follow-up visit at the time of enrollment, or
  2. Patients or his/her legally authorized representative objects to extraction of patient's data from the medical record, or unwilling to sign the .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No

Interventions

  • ProcedureEndovascular Aortic Treatments

    Use of Cook's custom-made endovascular grafts to treat complex abdominal, thoracoabdominal aortic diseases, or aortic arch diseases such as aneurysms and dissections.

06

What researchers measure

Primary outcomes

  1. Rate of treatment success

    Procedural treatment success is defined as successful access to the arterial system using remote arterial exposure, percutaneous technique or open surgical conduits. Success is also defined as successful delivery and deployment of the aortic graft and all stent components, side branch catheterization and placement of bridging stents and patency of all aortic modular stent graft components and intended side branch components.

    Time frame: 12 months

  2. Rate of safety outcomes

    Safety outcomes is defined as freedom from major adverse events (all-cause mortality, myocardial infarction, disabling stroke, renal failure requiring new-onset dialysis, respiratory failure requiring prolonged (\>24hrs) mechanical ventilation or reintubation, paraplegia, bowel ischemia requiring surgical resection or not resolving with medical therapy)

    Time frame: 30 days

07

Study locations

18 of 18 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05896397
Responsible party
Sponsor
First posted
Jun 9, 2023
Start date
May 31, 2023
Primary completion
Jan 2027 (estimated)
Completion
Dec 2030 (estimated)
Last update
Jun 4, 2026

Study contacts

Gregoire Masliah
Contact
gregoire.masliah@cookmedical.com
+41 795 490 954
Stephan Haulon, MD,PhD
principal investigator · Hopital Marie Lannelongue

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion